Cantor Fitzgerald Predicts OTCMKTS:ZLDPF FY2026 Earnings

Zealand Pharma A/S (OTCMKTS:ZLDPF) – Stock analysts at Cantor Fitzgerald issued their FY2026 earnings per share (EPS) estimates for Zealand Pharma A/S in a report released on Monday, June 9th. Cantor Fitzgerald analyst P. Agrawal expects that the company will earn $7.74 per share for the year. The consensus estimate for Zealand Pharma A/S’s current full-year earnings is ($2.19) per share.

Separately, William Blair upgraded shares of Zealand Pharma A/S from a “hold” rating to a “strong-buy” rating in a report on Friday, March 7th.

Zealand Pharma A/S Stock Down 2.2%

Zealand Pharma A/S stock opened at $74.13 on Thursday. The firm has a market capitalization of $5.26 billion, a price-to-earnings ratio of -31.41 and a beta of 0.74. The company’s 50 day simple moving average is $66.15 and its 200 day simple moving average is $85.91. The company has a debt-to-equity ratio of 0.03, a current ratio of 35.49 and a quick ratio of 35.49. Zealand Pharma A/S has a fifty-two week low of $57.97 and a fifty-two week high of $141.74.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last posted its earnings results on Thursday, May 8th. The company reported ($0.67) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.77) by $0.10. The company had revenue of $1.14 million during the quarter, compared to analyst estimates of $248.61 million. Zealand Pharma A/S had a negative return on equity of 15.24% and a negative net margin of 1,725.03%.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.